Patent Application
Utility
PCT National Stage
App. No. 17/638,741
· Confirmation No. 5641
BENZIMIDAZOLE AND HYDROGENATED CARBAZOLE DERIVATIVES AS GPX4 INHIBITORS
Applicant:
Ferro Therapeutics, Inc.
Abandoned -- Failure to Respond to an Office Action
View Publication ↗
|
⬇ PDF
|
Code | Description | Pages | ||
|---|---|---|---|---|---|
| 2025-05-20 | ABN |
Abandonment | 2 | View | |
| 2024-10-31 | CTRS |
Requirement for Restriction/Election | 10 | View | |
| 2024-10-31 | 892 |
List of references cited by examiner | 1 | View | |
| 2024-10-31 | FOR |
Foreign Reference | 193 | View | |
| 2022-11-15 | M903 |
Notice of Designated Office (DO) / Elected Office (EO) Acceptance Mailed | 2 | View | |
| 2022-11-15 | APP.FILE.REC |
Filing Receipt | 4 | View | |
| 2022-11-15 | WCLM |
Claims Worksheet (PTO-2022) | 1 | View | |
| 2022-11-15 | WFEE |
Fee Worksheet (SB06) | 1 | View | |
| 2022-11-07 | WFEE |
Fee Worksheet (SB06) | 2 | View | |
| 2022-11-07 | N417 |
Electronic Filing System Acknowledgment Receipt | 2 | View | |
| 2022-11-07 | WFEE |
Fee Worksheet (SB06) | 2 | View | |
| 2022-11-07 | N417 |
Electronic Filing System Acknowledgment Receipt | 2 | View | |
| 2022-11-07 | A.PE |
Preliminary Amendment | 1 | View | |
| 2022-11-07 | CLM |
Claims | 15 | View | |
| 2022-11-07 | REM |
Applicant Arguments/Remarks Made in an Amendment | 1 | View | |
| 2022-07-21 | NTC.PUB |
Notice of Publication | 1 | View | |
| 2022-04-08 | WCLM |
Claims Worksheet (PTO-2022) | 1 | View | |
| 2022-04-08 | APP.FILE.REC |
Filing Receipt | 3 | View | |
| 2022-04-08 | 371.FEE.M923 |
371 (National Stage) Supplemental Fees Missing - Form M923 | 2 | View | |
| 2022-04-08 | WFEE |
Fee Worksheet (SB06) | 1 | View | |
| 2022-02-25 | IDS |
Information Disclosure Statement (IDS) Form (SB08) | 2 | View | |
| 2022-02-25 | FOR |
Foreign Reference | 193 | View | |
| 2022-02-25 | FOR |
Foreign Reference | 228 | View | |
| 2022-02-25 | FOR |
Foreign Reference | 68 | View | |
| 2022-02-25 | FOR |
Foreign Reference | 213 | View | |
| 2022-02-25 | FOR |
Foreign Reference | 184 | View | |
| 2022-02-25 | REF.OTHER |
Other reference-Patent/Application/Search Documents | 20 | View | |
| 2022-02-25 | 371P |
Documents submitted with 371 (National Stage) Applications | 84 | View | |
| 2022-02-25 | WFEE |
Fee Worksheet (SB06) | 2 | View | |
| 2022-02-25 | N417 |
Electronic Filing System Acknowledgment Receipt | 4 | View | |
| 2022-02-25 | TRNA |
Transmittal of New Application | 4 | View | |
| 2022-02-25 | ADS |
Application Data Sheet | 6 | View | |
| 2022-02-25 | TRAN.LET |
Transmittal Letter | 2 | View | |
| 2022-02-25 | A.PE |
Preliminary Amendment | 1 | View | |
| 2022-02-25 | SPEC |
Specification | 1 | View | |
| 2022-02-25 | REM |
Applicant Arguments/Remarks Made in an Amendment | 1 | View | |
| 2022-02-25 | CLM |
Claims | 10 | View | |
| 2022-02-25 | SPEC |
Specification | 73 | View | |
| 2022-02-25 | FRPR |
Certified Copy of Foreign Priority Application | 67 | View | |
| 2022-02-25 | ABST |
Abstract | 1 | View | |
| 2022-02-25 | P.N.101.CONV |
PCT/RO/101 - Request form for new International Application - Conventional | 4 | View | |
| 2022-02-25 | FRPR |
Certified Copy of Foreign Priority Application | 73 | View | |
| 2022-02-25 | 371P |
Documents submitted with 371 (National Stage) Applications | 2 | View |
Inventors
Attorneys & Agents of Record
Classification
USPC
514/235.8
C07D235/30
A61P35/02
A61P35/00
A61K31/403
A61K31/5377
A61K45/06
C07D209/82
C07D401/04
C07D405/08
Prosecution
- Examiner
- KUCKLA, ANNA GRACE
- Art Unit
- 1626
- Customer No.
- 117795
- Docket No.
- 66EW-292851-US
- Confirmation No.
- 5641
Publication
- Pub. No.
- US20220227716A1
- Pub. Date
- 2022-07-21
Parent
PCT
is a National Stage Entry of
→
PCT/US2020/047989
Filed 2020-08-26
· Abandoned -- Failure to Respond to an Office Action
Parent
Claims priority from a provisional application
→
App. 62/893,130
Filed 2019-08-28
· Provisional Application Expired
Parent
Claims priority from a provisional application
→
App. 62/893,123
Filed 2019-08-28
· Provisional Application Expired
BRIDGEBIO PHARMA, INC.,
QED THERAPEUTICS, INC.,
EIDOS THERAPEUTICS, INC.,
ML BIO SOLUTIONS INC.,
CALCILYTIX THERAPEUTICS INC.,
ADRENAS THERAPEUTICS INC.,
PHOENIX TISSUE REPAIR, INC.,
NAVIRE PHARMA, INC.,
VENTHERA, INC.,
MOLECULAR SKIN THERAPEUTICS, INC.,
CANTERO THERAPEUTICS, INC.,
COA THERAPEUTICS, INC.,
PORTAL THERAPEUTICS, INC.,
BRIDGEBIO GENE THERAPY RESEARCH, INC.,
FERRO THERAPEUTICS, INC.
RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL
Recorded 2025-03-05
from
ADRENAS THERAPEUTICS INC.,
BRIDGEBIO GENE THERAPY RESEARCH, INC.,
BRIDGEBIO PHARMA, INC.,
CALCILYTIX THERAPEUTICS INC.,
CANTERO THERAPEUTICS, INC.,
COA THERAPEUTICS, INC.,
EIDOS THERAPEUTICS, INC.,
FERRO THERAPEUTICS, INC.,
ML BIO SOLUTIONS INC.,
MOLECULAR SKIN THERAPEUTICS, INC.,
NAVIRE PHARMA, INC.,
PHOENIX TISSUE REPAIR, INC.,
PORTAL THERAPEUTICS, INC.,
QED THERAPEUTICS, INC.,
SUB21, INC.,
THERAS, INC.,
VENTHERA, INC.
SECURITY INTEREST
Recorded 2024-01-19
from
ADRENAS THERAPEUTICS INC.,
BRIDGEBIO GENE THERAPY RESEARCH, INC.,
CALCILYTIX THERAPEUTICS INC.,
CANTERO THERAPEUTICS, INC.,
COA THERAPEUTICS, INC.,
FERRO THERAPEUTICS, INC.,
MOLECULAR SKIN THERAPEUTICS, INC.,
NAVIRE PHARMA, INC.,
PHOENIX TISSUE REPAIR, INC.,
PORTAL THERAPEUTICS, INC.,
SUB21, INC.,
VENTHERA, INC.
SECURITY INTEREST
Recorded 2024-01-17
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this application's details
Quick Facts
- App. No.
- 17/638,741
- Filed
- 2022-02-25
- Pub. No.
- US20220227716A1
- Examiner
- KUCKLA, ANNA GRACE
- Art Unit
- 1626
External Links